Samuel Wagner
About Samuel Wagner
Samuel Wagner is the Executive Director at Bristol-Myers Squibb, with a background in health economics and outcomes research. He has held leadership roles at Kantar Health, AstraZeneca, Pfizer, and Pharmacia, and has a long academic association with the University of Minnesota.
Current Title and Role
Samuel Wagner currently serves as the Executive Director at Bristol-Myers Squibb. In this pivotal role, he is influential in shaping strategic directions and overseeing significant projects within the organization. His leadership extends to multiple teams and high-impact initiatives, central to the company's success, particularly in Hematology and CAR T therapy.
Past Experience in Healthcare and Pharmaceuticals
Samuel Wagner's extensive experience in the healthcare and pharmaceutical industry includes several key positions. He was Vice President at Kantar Health for a year from 2008 to 2009. Before that, he worked as Director/Group Leader at AstraZeneca from 2006 to 2008. He spent seven years as Director at Pfizer from 1999 to 2006 and served as Associate Director at Pharmacia from 1999 to 2003. His diverse roles across these major organizations highlight his comprehensive expertise in the field.
Academic Background and Education
Samuel Wagner has a robust academic foundation in pharmaceutical sciences and healthcare economics. He holds multiple degrees from North-West University, including a B.Sc., BPharm, M.Pharm., HBA, and a PhD in Pharmaceutical Economics, Pharmacy, and Pharmaco-epidemiology. Additionally, he completed a Post-doc in Health Economics and Outcomes Research and Health Policy at the University of Minnesota from 1996 to 1999.
Development of Patient-Reported Outcomes Capability
At Bristol-Myers Squibb, Samuel Wagner played a critical role in leading the development of the Patient-Reported Outcomes (PRO) capability. This initiative was instrumental in enhancing the organization's ability to capture and analyze patient feedback, thereby augmenting the value and effectiveness of therapeutic solutions offered by the company.
Building Teams and Leading Economic Modeling Initiatives
Samuel Wagner has significantly contributed to team-building and economic modeling at Bristol-Myers Squibb. He built the Economic and Predictive Modeling team, laying the groundwork for sophisticated analytical approaches within the organization. Additionally, he has successfully established the Heme and CAR T HEOR team, exemplifying his ability to lead and develop high-performing units that drive the company’s research and commercial success.